Do analysts prefer OGI or ALGS?

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 727.60%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Organigram Global. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Does the media refer more to OGI or ALGS?

In the previous week, Organigram Global and Organigram Global both had 3 articles in the media. Organigram Global's average media sentiment score of 1.14 beat Aligos Therapeutics' score of 0.20 indicating that Organigram Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organigram Global 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AARD or ALGS?

In the previous week, Aardvark Therapeutics had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for Aardvark Therapeutics and 3 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.20 beat Aardvark Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IFRX or ALGS?

In the previous week, InflaRx had 3 more articles in the media than Aligos Therapeutics. MarketBeat recorded 6 mentions for InflaRx and 3 mentions for Aligos Therapeutics. InflaRx's average media sentiment score of 0.45 beat Aligos Therapeutics' score of 0.20 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PMN or ALGS?

In the previous week, Promis Neurosciences had 6 more articles in the media than Aligos Therapeutics. MarketBeat recorded 9 mentions for Promis Neurosciences and 3 mentions for Aligos Therapeutics. Promis Neurosciences' average media sentiment score of 0.63 beat Aligos Therapeutics' score of 0.20 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALGS or VTVT?

In the previous week, vTv Therapeutics had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for vTv Therapeutics and 3 mentions for Aligos Therapeutics. vTv Therapeutics' average media sentiment score of 0.22 beat Aligos Therapeutics' score of 0.20 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aligos Therapeutics (ALGS) Competitors

$4.65 +0.05 (+1.13%)

As of 01:44 PM Eastern

Compare

ALGS vs. OGI, AARD, IFRX, PMN, and VTVT

Should you buy Aligos Therapeutics stock or one of its competitors? MarketBeat compares Aligos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aligos Therapeutics include Organigram Global (OGI), Aardvark Therapeutics (AARD), InflaRx (IFRX), Promis Neurosciences (PMN), and vTv Therapeutics (VTVT).

How does Aligos Therapeutics compare to Organigram Global?

Organigram Global (NASDAQ:OGI) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Organigram Global has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

Organigram Global has a net margin of -9.22% compared to Aligos Therapeutics' net margin of -1,919.68%. Organigram Global's return on equity of -13.41% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram Global	-9.22%	-13.41%	-9.09%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 0.1% of Organigram Global shares are owned by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 727.60%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Organigram Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Organigram Global and Organigram Global both had 3 articles in the media. Organigram Global's average media sentiment score of 1.14 beat Aligos Therapeutics' score of 0.20 indicating that Organigram Global is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organigram Global	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organigram Global has higher revenue and earnings than Aligos Therapeutics. Organigram Global is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$185.07M	0.74	-$17.70M	-$0.13	N/A
Aligos Therapeutics	$2.19M	13.15	-$24.19M	-$8.69	N/A

Summary

Aligos Therapeutics beats Organigram Global on 9 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Aardvark Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aardvark Therapeutics' return on equity of -61.71% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Aardvark Therapeutics currently has a consensus price target of $16.30, indicating a potential upside of 123.50%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 727.60%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Aligos Therapeutics has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Aligos Therapeutics	$2.19M	13.15	-$24.19M	-$8.69	N/A

In the previous week, Aardvark Therapeutics had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for Aardvark Therapeutics and 3 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.20 beat Aardvark Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.4% of Aligos Therapeutics shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aardvark Therapeutics has a beta of 3.8, suggesting that its stock price is 280% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

Summary

Aardvark Therapeutics beats Aligos Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aligos Therapeutics compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

42.4% of InflaRx shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

InflaRx has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. InflaRx's return on equity of -88.30% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Aligos Therapeutics has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	4,265.11	-$51.63M	-$0.71	N/A
Aligos Therapeutics	$2.19M	13.15	-$24.19M	-$8.69	N/A

In the previous week, InflaRx had 3 more articles in the media than Aligos Therapeutics. MarketBeat recorded 6 mentions for InflaRx and 3 mentions for Aligos Therapeutics. InflaRx's average media sentiment score of 0.45 beat Aligos Therapeutics' score of 0.20 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InflaRx has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

InflaRx currently has a consensus target price of $7.00, indicating a potential upside of 295.48%. Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 727.60%. Given Aligos Therapeutics' higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

InflaRx beats Aligos Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Aligos Therapeutics compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Aligos Therapeutics has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Aligos Therapeutics	$2.19M	13.15	-$24.19M	-$8.69	N/A

Promis Neurosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

In the previous week, Promis Neurosciences had 6 more articles in the media than Aligos Therapeutics. MarketBeat recorded 9 mentions for Promis Neurosciences and 3 mentions for Aligos Therapeutics. Promis Neurosciences' average media sentiment score of 0.63 beat Aligos Therapeutics' score of 0.20 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Promis Neurosciences currently has a consensus target price of $31.50, indicating a potential upside of 132.88%. Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 727.60%. Given Aligos Therapeutics' higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Promis Neurosciences has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Aligos Therapeutics beats Promis Neurosciences on 11 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to vTv Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Aligos Therapeutics has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	13.15	-$24.19M	-$8.69	N/A
vTv Therapeutics	$1.02M	126.56	-$26.97M	-$0.93	N/A

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aligos Therapeutics has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

vTv Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. vTv Therapeutics' return on equity of 3.96% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
vTv Therapeutics	N/A	3.96%	2.86%

Aligos Therapeutics currently has a consensus price target of $38.50, suggesting a potential upside of 727.60%. vTv Therapeutics has a consensus price target of $56.67, suggesting a potential upside of 72.96%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, vTv Therapeutics had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for vTv Therapeutics and 3 mentions for Aligos Therapeutics. vTv Therapeutics' average media sentiment score of 0.22 beat Aligos Therapeutics' score of 0.20 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aligos Therapeutics beats vTv Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALGS vs. The Competition

Export

Metric	Aligos Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.97M	$3.55B	$6.82B	$12.97B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.54	7.36	279.98	25.51
Price / Sales	13.15	1,276.69	649.15	115.49
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	0.54	17.17	11.14	6.35
Net Income	-$24.19M	-$12.52M	$3.48B	$347.60M
7 Day Performance	9.46%	2.26%	2.39%	3.04%
1 Month Performance	-16.78%	-5.59%	-2.87%	-2.15%
1 Year Performance	-41.85%	50.75%	64.14%	21.14%

Aligos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALGS Aligos Therapeutics	3.1615 of 5 stars	$4.65 +1.1%	$38.50 +727.6%	-38.3%	$28.97M	$2.19M	N/A	90	Upcoming Earnings
OGI Organigram Global	0.9323 of 5 stars	$0.94 +1.7%	N/A	-27.5%	$133.20M	$185.07M	N/A	1,139	News Coverage Positive News Upcoming Earnings
AARD Aardvark Therapeutics	2.6254 of 5 stars	$6.08 +9.9%	$16.30 +168.1%	-41.6%	$133.03M	N/A	N/A	18	News Coverage
IFRX InflaRx	2.8069 of 5 stars	$1.81 -0.5%	$7.00 +286.7%	+103.5%	$130.85M	$30K	N/A	60	Upcoming Earnings
PMN Promis Neurosciences	3.5403 of 5 stars	$14.49 -3.8%	$24.00 +65.6%	-26.2%	$129.98M	N/A	N/A	5	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALGS) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aligos Therapeutics (ALGS) Competitors

ALGS vs. OGI, AARD, IFRX, PMN, and VTVT

How does Aligos Therapeutics compare to Organigram Global?

Summary

How does Aligos Therapeutics compare to Aardvark Therapeutics?

Summary

How does Aligos Therapeutics compare to InflaRx?

Summary

How does Aligos Therapeutics compare to Promis Neurosciences?

Summary

How does Aligos Therapeutics compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aligos Therapeutics (ALGS) Competitors

ALGS vs. OGI, AARD, IFRX, PMN, and VTVT

How does Aligos Therapeutics compare to Organigram Global?

Which has more risk & volatility, OGI or ALGS?

Is OGI or ALGS more profitable?

Do institutionals & insiders hold more shares of OGI or ALGS?

Do analysts prefer OGI or ALGS?

Does the media refer more to OGI or ALGS?

Which has higher earnings and valuation, OGI or ALGS?

Summary

How does Aligos Therapeutics compare to Aardvark Therapeutics?

Is AARD or ALGS more profitable?

Do analysts recommend AARD or ALGS?

Which has preferable earnings & valuation, AARD or ALGS?

Does the media refer more to AARD or ALGS?

Do institutionals and insiders believe in AARD or ALGS?

Which has more risk & volatility, AARD or ALGS?

Summary

How does Aligos Therapeutics compare to InflaRx?

Do insiders and institutionals believe in IFRX or ALGS?

Is IFRX or ALGS more profitable?

Which has better valuation and earnings, IFRX or ALGS?

Does the media prefer IFRX or ALGS?

Which has more volatility and risk, IFRX or ALGS?

Do analysts prefer IFRX or ALGS?

Summary

How does Aligos Therapeutics compare to Promis Neurosciences?

Which has stronger earnings & valuation, PMN or ALGS?

Is PMN or ALGS more profitable?

Does the media refer more to PMN or ALGS?

Do analysts prefer PMN or ALGS?

Which has more volatility & risk, PMN or ALGS?

Do insiders & institutionals believe in PMN or ALGS?

Summary

How does Aligos Therapeutics compare to vTv Therapeutics?

Which has higher earnings and valuation, ALGS or VTVT?

Do institutionals and insiders hold more shares of ALGS or VTVT?

Which has more risk and volatility, ALGS or VTVT?

Is ALGS or VTVT more profitable?

Do analysts rate ALGS or VTVT?

Does the media favor ALGS or VTVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools